Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.33 |
| ▸ | TUBB | P07437 | 2/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236433 | 0.92 | SMN1; SMN2 (0.42) | ERN1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL9945982 | 0.89 | ERN1 (0.39) | ERN1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL16687413 | 0.87 | ALDH1A1 (0.41) | ERN1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14316911 | 0.83 | ALDH1A1 (0.44) | ERN1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL273091 | 0.83 | ALDH1A1 (0.44) | ERN1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3790617 | 0.83 | LTA4H (0.41) | KMT2AMEN1LMNAMAPTHPGD | |
| SCHEMBL22594794 | 0.81 | PTGS1 (0.59) | KMT2AMEN1PTGS1PTGS2TUBB4A | |
| SCHEMBL24993379 | 0.77 | AHR (0.53) | ERN1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL29953751 | 0.77 | ENPP2 (0.46) | ERN1KMT2AMEN1ALDH1A1TUBB4A | |
| SCHEMBL29953064 | 0.77 | ELANE (0.43) | KMT2AMEN1ALDH1A1LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-9828346-B2 | N-myristoyl transferase inhibitors | UNIVERSITY OF DUNDEE (GB) | 2017-11-28 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2980076-B1 | Pyrazolyl derivatives | UNIV DUNDEE (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060224-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIVERSITY OF DUNDEE (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2980076-A1 | PYRAZOLYL DERIVATIVES | University of Dundee (GB) | 2016-02-03 | — | — | EP | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9156811-B2 | N-myristoyl transferase inhibitors | Univeristy of Dundee (GB) | 2015-10-13 | — | — | US | disclosed |
| EP-2323987-B1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIV DUNDEE (GB) | 2015-06-24 | — | — | EP | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110312921-A1 | N-Myristoyl Transferase Inhibitors | DUNDEE, UNIVERSITY OF (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2323987-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | University of Dundee (GB) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010026365-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIVERSITY OF DUNDEE (GB) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312921-A1 | N-Myristoyl Transferase Inhibitors | GNMT, NNMT, SPTLC1 | ERN1 1052/4885KDM4E 1479/4885KMT2A 1145/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | ERN1 3463/4885KDM4E 1517/4885KMT2A 1160/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ERN1 2855/4885KDM4E 4270/4885KMT2A 4328/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | ERN1 3463/4885KDM4E 1517/4885KMT2A 1160/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | ERN1 3463/4885KDM4E 1517/4885KMT2A 1160/4885 |
| US-20160060224-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | GNMT, NNMT, SPTLC1 | ERN1 1052/4885KDM4E 1479/4885KMT2A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.